{"id":26490,"date":"2021-10-26T15:23:01","date_gmt":"2021-10-26T14:23:01","guid":{"rendered":"https:\/\/touchneurology.com\/?post_type=media_gallery&p=26490"},"modified":"2021-10-26T15:23:51","modified_gmt":"2021-10-26T14:23:51","slug":"barry-singer-ectrims-2021-flushing-and-flushing-related-adverse-events-results-from-the-phase-3-evolve-ms-2-study","status":"publish","type":"media_gallery","link":"https:\/\/touchneurology.com\/multiple-sclerosis\/conference-hub\/barry-singer-ectrims-2021-flushing-and-flushing-related-adverse-events-results-from-the-phase-3-evolve-ms-2-study\/","title":{"rendered":"Barry Singer, ECTRIMS 2021: Flushing and Flushing-related Adverse Events – Results from the Phase 3 EVOLVE-MS-2 Study"},"content":{"rendered":"

It was a pleasure to meet with Dr Barry Singer<\/strong> (The MS Center for Innovations in Care, Missouri Baptist Medical Center, St. Louis, MO, USA) to discuss the results of the phase 3 EVOLVE-MS-2 study, specifically looking at flushing and flushing related-adverse events with diroximel fumarate in patients with relapsing remitting multiple sclerosis.<\/p>\n

The abstract entitled: \u2018Flushing and flushing-related adverse events with diroximel fumarate in patients with relapsing remitting multiple sclerosis: results from the Phase 3 EVOLVE-MS-2 Study\u2019 was presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 13-15 October 2021.<\/p>\n

Questions<\/strong>:<\/p>\n

    \n
  1. What are the advantages of diroximel fumarate compared with dimethyl fumarate in the treatment of patients with relapsing remitting MS? (0:13)<\/li>\n
  2. What is known about the incidence of flushing with dimethyl fumarate treatment? (1:02)<\/li>\n
  3. What were the objectives of this analysis of the EVOLVE-MS study data? (1:42)<\/li>\n
  4. What were the findings in terms of flushing incidence and severity? (2:30)<\/li>\n
  5. What were the limitations of this analysis and what future studies are needed? (3:14)<\/li>\n<\/ol>\n

    Disclosures<\/strong>: Barry Singer has received research grant support and speaking\/consulting honorarium from Biogen.<\/p>\n

    Support<\/strong>: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch<\/p>\n

    Filmed as a highlight of ECTRIMS, Virtual 2021<\/strong><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

    It was a pleasure to meet with Dr Barry Singer (The MS Center for Innovations in Care, Missouri Baptist Medical Center, St. Louis, MO, USA) to discuss the results of the phase 3 EVOLVE-MS-2 study, specifically looking at flushing and flushing related-adverse events with diroximel fumarate in patients with relapsing remitting multiple sclerosis. The abstract […]<\/p>\n","protected":false},"featured_media":26491,"template":"","class_list":["post-26490","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-multiple-sclerosis","video_categories-ectrims-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery\/26490"}],"collection":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":2,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery\/26490\/revisions"}],"predecessor-version":[{"id":26493,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery\/26490\/revisions\/26493"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media\/26491"}],"wp:attachment":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media?parent=26490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}